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Abstract 
 
The detrimental effects of cigarette use during pregnancy are well documented.  Studies have 
shown that cigarette smoking while pregnant is associated with multiple adverse outcomes 
including pre-term birth, placental abruption, placenta previa, fetal growth restriction, stillbirth, 
increased rate of birth defects, and increased risk of sudden infant death syndrome. Cotinine is 
the primary metabolite of nicotine and allows for measurement of active as well as passive 
exposure.  Cotinine freely crosses the placental barrier and maternal concentrations are closely 
correlated with newborn plasma levels.  The aim of this study was to compare maternally 
reported rates of tobacco use to fetal umbilical cord blood cotinine levels at the time of delivery.  
A cross-sectional study was conducted on 172 patients.  Patients were asked a single yes or no 
question in regards to their cigarette use during pregnancy.  Cord blood was collected at the time 
of delivery and analyzed for serum concentrations of cotinine.  Cotinine levels greater than 3.0 
ng/mL were considered consistent with the use of tobacco or tobacco cessation products.  
Maternal self-reporting of tobacco use indicates a reported tobacco use rate of 27.3% and an 
actual use rate of 30.2%.  The reported tobacco non-use rate was 72.7% and the actual non-use 
rate was 66.3%.  The prevalence of tobacco use during pregnancy in our study was 30.2%, while 
the overall rate in the United States is reported to be 12.3%.  Our findings indicate that self-
reported smoking prevalence and verified umbilical cord blood cotinine levels at the time of 
delivery have excellent correlation (kappa=0.76).  Compared to the national average our study 
group also had nearly double the rate of tobacco use.  Due to the deleterious effects of cigarette 
use during pregnancy continued efforts to educate patients regarding cigarette cessation is of 
utmost importance as cessation of tobacco products will improve and promote maternal and fetal 
well-being. 
 
Keywords 
cigarette, Appalachia, gravida, fetus, smoking, nicotine, cotinine 
 
Introduction 
 
The detrimental effects of cigarette use during pregnancy are well documented.  Studies have 
shown that cigarette smoking is associated with multiple adverse outcomes during pregnancy 
including pre-term birth, placental abruption, placenta previa, fetal growth restriction, stillbirth, 
increased rate of birth defects, and increased risk of sudden infant death syndrome.1  
 
The adverse effects of cigarette use extend beyond prenatal exposure.  Nicotine is associated 
with adverse postnatal neurobehavioral, metabolic, cardiovascular, and respiratory outcomes, 
sudden infant death syndrome (SIDS) and childhood cancers.2-4  Nicotine is a neurological 
stimulant and considered a major contributor to the addictive effect of tobacco products.  
Cotinine is the primary metabolite of nicotine and allows for measurement of active as well as 
passive exposure.  Cotinine freely crosses the placental barrier and maternal concentrations are 
strongly correlated with newborn plasma levels.5,6  
 
Overall the rate of reported smoking during pregnancy in the United States has decreased from 
18.4% in 1990 to 12.3% in 2010.7,8  However, in the Pregnancy Risk Assessment Monitoring 
System, Tong et al reported that West Virginia was one of three states where smoking prevalence 
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increased between 1990-2010.8 The smoking prevalence in the state of West Virginia is 67% 
among adolescents between the age of 13-19 during the last 3 months of pregnancy.9 
 
The aim of this study was to compare and correlate maternally reported rates of tobacco use to 
fetal cord blood levels of cotinine at the time of delivery among Appalachian gravidas. An 
additional objective was to examine the accuracy of self-reporting for smoking status in pregnant 
women. There is a lack of studies examining the frequency of tobacco use in Appalachia. The 
health effects of smoking are well recognized but discontinuation of smoking is a modifiable 
source of prenatal and perinatal morbidity and mortality. Identifying a higher than the national 
average frequency of tobacco usage supports the need to further educate the public regarding the 
adverse effects of smoking during pregnancy. 
 
Methods 
   
A cross-sectional study was conducted on 172 patients from April 2013 to February 2014. 
Inclusion criteria were consenting patients presenting to the labor and delivery unit at Cabell 
Huntington Hospital in active labor or admitted for induction of labor.  Exclusion criteria were 
patients who delivered precipitously prior to being consented for the study.  The study 
participants were asked a single yes or no question in regard to cigarette use during pregnancy.  
Cord blood was collected at the time of delivery and analyzed for serum concentrations of 
cotinine in ng/mL by the Cabell Huntington Hospital laboratory.  
 
For the purpose of this study cotinine levels greater than 3.0 ng/mL were considered consistent 
with the use of tobacco or tobacco cessation products.10  A serum cord blood cotinine level of 
<3.0 ng/mL would classify a patient as a “non-tobacco user” and cotinine level of >3.0 ng/mL 
would classify a patient as a “tobacco user”.  Self-reported maternal smoking data was collected 
at the time of admission and results were corroborated with cord blood analysis for cotinine.  
Demographic information was extracted from the subjects’ electronic medical records.   
 
Approval from the Institutional Review Board at Marshall University was obtained prior to 
beginning the study. Statistical analysis for continuous variables was by independent sample t-
test using SAS Enterprise Guide 7.1. The project was supported by the Robert C. Byrd Center for 
Rural Health, Marshall University, and funding was obtained through the Rural Health Initiative 
grant from the West Virginia Higher Education Policy Commission and the Marshall University 
School of Medicine Translational Research Pilot Grant program.  
 
Results 
  
The overall prevalence of tobacco products in our study using a cotinine cutoff of  >3.0 ng/mL 
was 30.2% (Table 1).  There were 41 patients who reported tobacco use whose cord cotinine 
levels were positive at >3.0 ng/mL and 6 patients who reported tobacco use and cord cotinine 
levels were measured <3.0 ng/mL.  There were 114 patients who denied tobacco use whose cord 
cotinine levels were negative and 11 patients who denied tobacco use while cord cotinine was 
>3.0 ng/mL.  Comparing maternal reports of tobacco use indicates a reported tobacco use rate of 
27.3% and an actual use rate as measured by cotinine in cord blood of 30.2%.  The reported 
tobacco non-use rate was 72.7% and the actual non-use rate was 66.3%.   
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Self-reported tobacco use showed excellent agreement with the cotinine levels measured in 
umbilical cord blood with a Cohen’s kappa coefficient of 0.76 (0.61-0.80 is excellent 
agreement).11 In our study a single yes or no question in regard to maternal tobacco use has a 
sensitivity of 79%, specificity of 95%, positive predictive value of 87% and negative predictive 
value of 91%. 
 
Table 1: Correlation of maternal self-report and umbilical cord blood cotinine levels 
Maternal Self-Report Cord Cotinine >3.0 ng/mL Cord Cotinine <3.0 ng/mL Total 
Yes 41 6 47 
No 11 114 125 
Total 52 120 172 
 
Prevalence of tobacco use: 30.2% 
Sensitivity 79% 
Specificity 95% 
Positive Predictive Value 87% 
Negative Predictive Value 91% 
Kappa = 0.76 (0.61-0.80 is excellent agreement)11 
 
Baseline characteristics were similar among our tobacco non-users and users for maternal age, 
BMI, race, urbanization, hemoglobin and hematocrit levels on admission, mode of delivery, 
estimated blood loss at the time of delivery, gestational age, hypertension, diabetes, and length of 
hospital stay (Table 2).  Among the two groups there were no significant differences when 
comparing total pregnancies or pregnancy outcomes (term, preterm, abortions, living children).  
Maternal tobacco users were noted to be less likely to be married (17.3% vs. 57.5%), more likely 
to admit to substance abuse or dependence (26.92% vs. 2.50%), more likely to have Medicaid for 
insurance (86.54% vs. 49.17%), and more likely to be unemployed (73.08% vs. 54.17%). 
 
Table 2: Maternal Information.  Reported mean + SD for continuous variables or n (%) for 
categorical variables. 95% Confidence Interval. 
 Tobacco Non-User 
(cotinine <3 ng/mL) 
Tobacco User  
(cotinine >3 ng/mL) 
p-value 
Age 25.92+5.53 25.13+4.15 0.31 
BMI 32.46+6.53 30.46+7.77 0.08 
Cotinine Level (ng/mL) 0.09+.34 69.65+59.46 <.0001 
Race    
     White 113 (94.17) 51 (98.08)  
     Other 7 (5.83) 1 (1.92)  
Marital Status    
     Married 69 (57.5) 9 (17.31)  
     Other 51 (42.5) 43 (82.69)  
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Self-Reported Substance 
Abuse/Dependence 
3 (2.50) 14 (26.92)  
Urbanization    
     Urban 63 (52.5) 30 (57.69)  
     Rural 57 (47.5) 22 (42.31)  
Insurance Type    
     Private 57 (47.5) 5 (9.62)  
     Medicaid 59 (49.17) 45 (86.54)  
     None 4 (3.33) 2 (3.85)  
Employment    
     Employed 55 (45.83) 14 (26.92)  
     Not-Employed 65 (54.17) 38 (73.08)  
Mother Length of Hospital Stay 
(days) 
3.76+3.84 3.40+2.08 0.44 
Maternal Hypertension 25 (20.83) 11 (21.15)  
Maternal Diabetes 12 (10) 4 (7.69)  
Maternal Hemoglobin (g/dL) 11.74+1.22 11.87+1.23 0.53 
Maternal Hematocrit (%) 35.31+3.85 35.84+3.46 0.39 
Mode of Delivery    
     Cesarean Delivery 31 (25.83) 18 (34.62)  
     Vaginal Delivery 89 (74.17) 34 (65.38)  
Gestational Age at Delivery 
(weeks) 
38.32+2.08 38.48+1.91 0.62 
Estimated Blood Loss at Time 
of Delivery (mL) 
395.4+195.4 423.8+229.2 0.41 
 
Fetal outcomes were significantly different in regard to fetal weight, length of neonatal hospital 
stay, and neonatal intensive care unit admission (Table 3).  Mean weight was 3311+65g in the 
non-tobacco users and 3057+60 in the tobacco users (mean+SD), with a p-value of 0.02.  This 
finding is consistent with previously published literature.1   Hospital length of stay for the infants 
was noted to be significantly different, with infants of tobacco non-users staying 5.08+9.62 days 
and infants of tobacco users staying 10.65+13.40 (mean+SD), p-value of 0.009.  Infants born to 
tobacco users were also twice as likely to go to the NICU with 32.69% (n=17) of tobacco users 
and only 15.83% (n=19) of non-tobacco users infants being admitted to the unit. 
 
Table 3: Fetal Information. Reported as mean + SD for continuous variables or n (%) for 
categorical variables.  95% Confidence Interval. 
Gender Tobacco Non-User 
(cotinine <3 ng/mL) 
Tobacco User 
(cotinine >3 ng/mL) 
p-value 
     Male 65 (54.17) 28 (53.85)  
     Female 55 (45.83) 24 (46.15)  
1 Minute Apgar 8.28+1.20 8.31+0.88 0.88 
5 Minute Apgar 8.97+0.29 8.85+0.46 0.08 
Birth Weight (grams) 3311+65 3057+60 0.02 
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Baby Length of Hospital Stay 
(days) 
5.08+9.62 10.65+13.40 0.009 
Head Circumference (cm) 33.99+3.62 33.81+1.87 0.67 
Fetal Height (cm) 165.3+7.17 165.6+7.01 0.80 
Immediate Post-Partum 
Location 
   
     Well-Born Nursery 101 (84.17) 35 (67.31)  
     NICU 19 (15.83) 17 (32.69)  
 
Discussion 
 
West Virginia currently ranks first in United States with 27 of every 100 adults being tobacco 
users.12,13 A recent report indicated that 67% of West Virginia pregnant adolescents 19 years of 
age or younger smoked during the last 3 months of pregnancy.9 Overall the rate of reported 
smoking during pregnancy in the United States is 12.3%.7,8  Our study indicates that smoking 
prevalence (based on a cotinine level of >3.0 ng/mL) at the time of delivery among Appalachian 
gravidas was 30.2%.  These findings indicate that self-reported smoking prevalence and verified 
umbilical cord blood cotinine levels at the time of delivery were much higher than the national 
average in the United States. Our study is the first to correlate umbilical cord cotinine levels in 
babies born in West Virginia with self reported smoking habit of the mothers during pregnancy.  
 
The results of our study are consistent with previous inquires examining self-reported tobacco 
use among pregnant women and the correlation with serum concentrations of cotinine.  A study 
of 448 women using a maternal serum cotinine concentration of >10.0 ng/mL to define tobacco 
users determined that 94.9% of women who denied smoking and 87.0% of women who stated 
they smoked reported their status accurately (kappa=0.83).14  Kvalvik et al studied a subsample 
of 2,997 women in the Norwegian Mother and Child Cohort Study (MoBa) to assess self-
reported tobacco use and plasma cotinine concentrations at 18 weeks gestational age using a 
cutoff of 12ng/mL.15  The sensitivity and specificity for self-reported smoking was 82% and 99% 
respectively.  In our study a cotinine level of 3.0 ng/ml or higher was considered positive for  
exposure to tobacco usage and this value was based on  a previous report by another laboratory.10  
This cutoff was adopted for our study as our mothers were of different races and the lower level 
will include individuals that occasionally smoke.  Cotinine levels resulting from exposure to 
second-hand smoke has declined over the past 30 years due to increased smoke free public areas. 
Cotinine levels in nonsmokers exposed to second-hand smoke are less than 1 ng/ml;10 it is 
unlikely that second-hand smoke exposure was identified as a smoker in our study as our cutoff 
level was 3.0 ng/ml.  
 
Intervention strategies to promote cessation of tobacco use, prevent relapse, and avoid 
secondhand smoke exposure are essential and should be incorporated during routine prenatal 
visits.16 Techniques for intervention range from counseling, cognitive and behavioral therapy, 
hypnosis, acupuncture to pharmacologic therapy.17,18 Each method may have a different effect 
and outcome, so it is important to individualize the approach for each patient and provide the 
risks and benefits that are associated with each option. Smoking cessation prior to 15 weeks 
gestation has been shown to provide the greatest benefits for both the fetus and the mother, 
however, cessation of smoking at anytime during the pregnancy has shown to be beneficial.19,20 
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In fact, cessation prior to the third trimester can offer a significant reduction in the low birth 
weight that is caused by maternal smoking.20  
 
This study does have limitations.  The self-reported daily amount of cigarettes smoked was 
obtained however it was not ascertained when the study participants last had a cigarette prior to 
presenting to the labor and delivery unit.  Perhaps this could be a contributing factor to our 
patients who reported using tobacco products but the resultant umbilical cord blood for cotinine 
was negative.  Another contributing factor could be innate differences in regard to the fetal 
metabolism of nicotine and its metabolite cotinine that was measured for this study.  Further 
studies are needed in the area of fetal metabolism of tobacco products.  There was also the 
potential for selection bias as all patients who presented to the labor and delivery unit were not 
enrolled in the study. 
 
In our study of Appalachian gravidas self-reported smoking prevalence and verified umbilical 
cord blood cotinine levels at the time of delivery have excellent correlation.  Compared to the 
national average our study group also had nearly double the rate of tobacco use.  Due to the 
deleterious effects of cigarette use during pregnancy continued efforts to educate patients 
regarding cigarette cessation is of utmost importance as cessation of tobacco products will 
improve and promote maternal and fetal well-being. 
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